Atrophic Vaginitis When Initial Treatments Have Not Adequately Improved Symptoms

For patients with atrophic vaginitis whose symptoms — including vulvovaginal dryness, dyspareunia, and discomfort or irritation — have not responded sufficiently to first-line therapies, a structured next-line protocol applies.

Prior treatment — insufficient response

First-line management is typically chosen through shared decision-making and may include local low-dose vaginal estrogen (cream, tablet, or ring), vaginal DHEA, oral ospemifene, vaginal moisturizers or lubricants, and avoidance of vulvovaginal irritants.

Escalation to a next-line protocol is indicated when vulvovaginal dryness, dyspareunia, and discomfort or irritation have not begun improving within approximately 1–2 months of initiating that treatment, or have not continued to improve through 12 weeks.

Next-line approach — partial overview

For patients who have not responded to, or are not candidates for, the standard options above, an energy-based procedural intervention may be considered — undertaken through shared decision-making and with clear disclosure of its current standing outside routine clinical approvals. The complete structured regimen and decision criteria are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

In the context of shared decision-making, and with the disclosure that these therapies are considered experimental outside of clinical trials, clinicians may consider CO2 laser treatment in patients who are not candidates for, or prefer alternatives to, FDA-approved treatments for GSM-related vulvovaginal dryness, vulvovaginal discomfort/irritation, dysuria, and/or dyspareunia.

DOI: 10.1097/JU.0000000000004589

View source ↗